COO vs LLY: fair value comparison
The Cooper Companies, Inc. and Eli Lilly and Company · Updated 2026-10-19
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, COO currently sits closer to the top of our ranking by discount to fair value.
| COO | LLY | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $54.37 | $1,179.27 |
| 12-month range | $53.27–$84.32 | $813.53–$1,280.34 |
| Rank by discount to fair value | #8 of 108 Healthcare | #9 of 108 Healthcare |
| Quality grade | B | B |
| Momentum grade | — | B |
| Leverage | Low | High |
| Margin trend | Contracting | Expanding |
| Revenue growth | Modest | High |
| RSI zone | Neutral | Overbought |
| 50/200-day trend | Downtrend | — |
| DCF cross-check | Overvalued | — |
| 52-week position | The bottom quarter | The top quarter |
Full single-stock breakdowns: COO fair value analysis · LLY fair value analysis